#pancreatic cancer

Revolution Medicines has started shipping an experimental pancreatic cancer drug, and its CEO says an FDA submission is coming soon.

Researchers say a dual-threshold approach to CA19-9 could identify pancreatic cancer patients with dangerous disease who appear low risk under the standard cutoff because of a genetic nonproducer status.

A study described in Gut found an AI model could flag subtle pancreatic changes in previously cleared CT scans, potentially opening a path to earlier intervention against one of the deadliest cancers.

A new tumor-on-a-chip model is aimed at reproducing the dense tissue environment around pancreatic tumors, giving researchers a closer look at how cancer and scar tissue interact and why treatment resistance is so common

At the AACR 2026 meeting, Revolution Medicines said new results for its KRAS-targeting pancreatic cancer pill were unusually strong, putting fresh attention on one of oncology’s most watched drug classes.

A pancreatic cancer drug candidate from Revolution Medicines, daraxonrasib, is being described as one of the most promising developments in decades, with early signs of unusually strong results against a target long seen

A randomized phase 2 trial in Nature Medicine found that adding elraglusib to gemcitabine plus nab-paclitaxel improved median overall survival and one-year survival in previously untreated metastatic pancreatic ductal ad

A Northwestern-developed drug reportedly doubled one-year survival in a pancreatic cancer trial, a notable signal in one of oncology’s most difficult treatment areas.